Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANDROID 25 vs HEXABRIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.
Hexabrix is an ionic, high-osmolar iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures. Its mechanism is physical rather than pharmacological, based on iodine's atomic number and density.
Hypogonadism in males (primary and secondary),Delayed puberty in males,Metastatic breast cancer in women (as palliative therapy)
Intravascular administration for arteriography, venography, and computed tomography (CT) imaging,Intrathecal administration for myelography (lumbar, thoracic, cervical, and total columnar myelography),Off-label: Arthrography, hysterosalpingography, and ductography
Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.
Intravenous: 0.3-0.6 m L/kg (maximum 100 m L) for urography; 40-80 m L for CT enhancement.
Terminal elimination half-life: 10–100 minutes (testosterone); clinical context: rapid clearance necessitates frequent dosing or use of esters for sustained effect
Terminal elimination half-life: 1.5–2 hours in adults (prolonged in renal impairment; up to 30 hours in severe CKD)
Primarily hepatic via reduction and oxidation; metabolites include androsterone and etiocholanolone; excreted in urine.
Not metabolized; eliminated unchanged via glomerular filtration by the kidneys.
Renal: 90% (as glucuronide and sulfate conjugates, 5–10% unchanged); fecal/biliary: 10%
Renal: 95% unchanged via glomerular filtration; Biliary: <5%; Fecal: <1%
97–99% (sex hormone-binding globulin and albumin)
Negligible (<5%); no specific binding proteins
0.3–0.6 L/kg; indicates distribution into lean muscle and sex organs
0.3–0.4 L/kg (confined to extracellular space; does not cross intact blood-brain barrier)
Oral: <5% (methyltestosterone: ~20–25% due to 17α-alkylation); IM: 100%
Intravenous/Intra-arterial: 100%; Oral: 0% (not absorbed)
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose or increasing interval; monitor for fluid retention and hypertension.
Contraindicated in patients with GFR <30 m L/min/1.73m². For GFR 30-59 m L/min, reduce dose by 50% and ensure adequate hydration.
Contraindicated in Child-Pugh class B or C cirrhosis. For mild hepatic impairment (Child-Pugh A), start with lower dose (e.g., 12.5 mg every 2 weeks) and titrate based on response and liver function.
No specific Child-Pugh based adjustments; use caution in severe hepatic impairment due to risk of hepatorenal syndrome.
Not recommended for use in pediatric patients (safety and efficacy not established). For male adolescents with hypogonadism, individualize: start at 12.5 mg every 2 weeks and adjust based on testosterone levels and growth.
Intravenous: 0.5-1 m L/kg (maximum 2 m L/kg) for urography; not recommended for neonates due to risk of acute renal failure.
Start with lower initial dose (e.g., 12.5 mg every 2 weeks); monitor prostate-specific antigen (PSA) and hematocrit frequently. Avoid in patients with prostate cancer or untreated sleep apnea.
Reduce dose by 25-50% in patients >70 years; maintain hydration and monitor renal function.
WARNING: Androgens are contraindicated in pregnancy due to masculinization of female fetus. Hepatotoxicity, including peliosis hepatis and hepatic neoplasms, has been reported with prolonged use.
Risk of severe, life-threatening adverse reactions including anaphylaxis, cardiovascular collapse, and seizures. Use only when diagnostic information is essential. Resuscitative equipment and trained personnel must be immediately available.
Use with caution in patients with hepatic, renal, or cardiovascular disease; may cause gynecomastia, edema, hypercalcemia, and polycythemia; monitor liver function, lipid profile, and hematocrit periodically; may accelerate bone maturation in children; risk of prostate hypertrophy and urethral obstruction.
Risk of acute renal failure, particularly in patients with pre-existing renal impairment, diabetes, or dehydration. Caution in patients with cardiovascular disease, asthma, or known hypersensitivity. Avoid extravasation. Thyroid function tests may be affected. Ensure adequate hydration before and after administration.
Known or suspected prostate cancer; male breast cancer; pregnancy; lactation; hypersensitivity to methyltestosterone; severe hepatic impairment.
Absolute: Known hypersensitivity to iodinated contrast media, overt thyrotoxicosis, anuria or severe oliguria due to renal disease. Relative: Myeloma, pheochromocytoma, sickle cell disease, pregnancy, and concomitant use of nephrotoxic drugs.
Take with food containing fat (e.g., avocado, nuts, olive oil) to enhance absorption. Avoid grapefruit juice as it may increase testosterone levels via CYP3A4 inhibition. Limit alcohol due to potential liver effects.
No specific food interactions. Maintain adequate hydration; alcohol should be avoided as it may increase dehydration risk.
Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure occurs before 12 weeks gestation. Second and third trimesters: Continued risk of female pseudohermaphroditism, and potential for masculinization of female external genitalia. Androgens can cross the placenta and may also cause skeletal abnormalities and growth retardation. Pregnancy category X.
HEXABRIX (ioxaglate meglumine and ioxaglate sodium) is an iodinated contrast agent. In animal studies, no teratogenic effects were observed. In humans, there is no evidence of fetal harm from diagnostic doses, though theoretical risks from free iodide exist, especially in the third trimester. The American College of Radiology recommends use only if clearly needed, with minimal dose.
Methyltestosterone is excreted into breast milk; M/P ratio not established. May cause virilization in female infants and premature sexual development in male infants. Androgens can suppress lactation. Use during breastfeeding is contraindicated.
Iodinated contrast agents are excreted into breast milk in very small amounts (<0.01% of maternal dose). The M/P ratio is not established. Breastfeeding can continue without interruption, but some sources suggest discarding milk for 12-24 hours if desired.
Android 25 is contraindicated in pregnancy, so no dosing adjustments are applicable. If used inadvertently, discontinue immediately. No pharmacokinetic data to guide dose changes; avoid use entirely.
No dose adjustment is recommended for pregnancy. However, use the lowest necessary dose to achieve diagnostic image. Renal function may be altered in pregnancy; ensure adequate hydration to prevent contrast-induced nephropathy.
Android 25 (testosterone undecanoate) requires absorption via lymphatic system; administer with fat-containing meal. Monitor serum testosterone levels 3-5 hours post-dose. Avoid in patients with breast cancer or known or suspected prostate cancer. Risk of polycythemia; check hematocrit before and during therapy.
HEXABRIX (ioxaglate meglumine and ioxaglate sodium) is a low-osmolar, ionic, dimeric contrast medium used for intravascular administration. It has lower osmolality than conventional ionic monomers, reducing the risk of contrast-induced nephropathy and hemodynamic disturbances. Ensure adequate hydration before and after administration. Caution in patients with renal impairment, diabetes, multiple myeloma, or prior contrast reactions. Do not mix with other drugs. Monitor for delayed hypersensitivity reactions.
Take capsules with meals, especially those containing fat, to improve absorption.,Do not chew or crush capsules; swallow whole.,Report signs of deep vein thrombosis (leg swelling, pain) or pulmonary embolism (sudden dyspnea, chest pain).,Women of reproductive potential should avoid pregnancy; use effective contraception.,Keep out of reach of children; testosterone can cause serious harm if accidentally ingested.,Regular blood tests (testosterone, hematocrit, PSA, lipid profile) are required.
Inform your doctor if you have kidney disease, diabetes, or any allergies, especially to contrast agents.,Drink plenty of fluids before and after the procedure to stay hydrated.,You may experience a warm sensation or metallic taste during injection; this is normal.,Report any symptoms like hives, itching, difficulty breathing, or swelling after the scan.,If you take metformin, you may need to stop it temporarily as directed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANDROID 25 vs HEXABRIX, answered by our medical review team.
ANDROID 25 is a Androgen that works by Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.. HEXABRIX is a Contrast Media that works by Hexabrix is an ionic, high-osmolar iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures. Its mechanism is physical rather than pharmacological, based on iodine's atomic number and density.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANDROID 25 and HEXABRIX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANDROID 25 is: Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.. The standard adult dose of HEXABRIX is: Intravenous: 0.3-0.6 m L/kg (maximum 100 m L) for urography; 40-80 m L for CT enhancement.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANDROID 25 and HEXABRIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANDROID 25 is classified as Category C. Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure oc. HEXABRIX is classified as Category C. HEXABRIX (ioxaglate meglumine and ioxaglate sodium) is an iodinated contrast agent. In animal studies, no teratogenic effects were observed. In humans, there is no evidence of feta. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.